Psychedelics and OCD

Psychedelics and OCD is one of the 'psychedelics and ...' topics that we're currently making a page for. At this moment you can find all papers (in our database) on this topic below.

Research Papers Compared Measured Researchers Gaps Companies

State of Research

TBD

Quality of Conclusions

TBD

Data Points

TBD Papers studying this directly
TBD Companies working on this

Access all our research

Become a free member now to get unlimited access.

Receive our weekly update on the latest psychedelic research, make (private) notes on pages, and download our reports.

Our vision is that psychedelics can be used worldwide to better the lives of as many as 450 million people who suffer from mental health problems. Our information hopes to make that vision come to life just a little faster.

OCD Research

Here will be a narrative, readable, summary of the research.

Papers

In our literature study we came across the following studies of note. Browse the meta, review, commentary articles for an overview. Check out the individual studies for specific experiments and observations.

Registered clinical studies investigating psychedelic drugs for psychiatric disorders

2021 | Gill, H., Lipsitz, O., Lui, L. M. W., McIntyre, R. S., Rosenblat, J. D., Siegel, A. N., Teopiz, K. M.

This review (2021) summarizes the study characteristics of all ongoing registered clinical trials investigating psychedelic drugs for psychiatric disorders and identifies that their majority focuses on investigating MDMA and psilocybin for treating depression or PTSD, while only 30% of their results are published.

Clinical and biological predictors of psychedelic response in the treatment of psychiatric and addictive disorders: a systematic review

2021 | Benyamina, A., Hermand, M., Karila, L., Pétillion, A., Romeo, B.

This systematic review (2021) of studies from 1990 to 2020 aimed to determine factors that can predict successful response to psychedelic treatment. In a variety of disorders, the authors found that the intensity of the experience was the best such predictor.

Therapeutic effects of classic serotonergic psychedelics: A systematic review of modern-era clinical studies

2020 | Andersen, K. A. A., Carhart-Harris, R. L., Erritzoe, D., Nutt, D. J.

This systematic review (2020) looked at 10 modern studies (n=188) on psychedelics (psilocybin, ayahuasca, LSD) for the treatment of a variety of mental health disorders. The review found the studies to provide evidence for efficacy (up to months later) and safety.

A potential role for psilocybin in the treatment of obsessive-compulsive disorder

2020 | Jacobs, E.

A comprehensive (2020) review of psilocybin in the treatment for OCD. The current research is limited in scope, but points towards possible mechanisms and effectiveness.

In vivo effects of ketamine on glutamate-glutamine and gamma-aminobutyric acid in obsessive-compulsive disorder: proof of concept

2015| Flood, P., Hunter, L., Kegeles, L. S., Levinson, A., Mao, X., Milak, M. S., Moore, H., Ogden, R. T., Rodriguez, C. I., Shungu, D. C., Simpson, H. B., Vermes, D., Xie, S.

This randomized, placebo-controlled, crossover trial study (n=17) investigates concurrent neurochemical effects of ketamine on glutamate-glutamine and gamma-aminobutyric acid in obsessive-compulsive disorder (OCD). It suggested that models of OCD pathology should examine the role of GABAergic abnormalities in OCD symptomatology.

Mental health of a self-selected sample of psychedelic users and self-medication practices with psychedelics

2018| Kuypers, K. P. C., Mason, N. L.

The observational survey study (n=1,967) investigated the frequency and efficacy of self-medication practices amongst psychedelic users and found that the prevalence of lifetime psychopathologies amongst psychedelic users was higher than in the general population. Although psychedelics were seldom used for self-medication, those who did use psychedelics in this manner reported it to be more effective than the current lines of treatment for mental illness.

Psilocybin and obsessive compulsive disorder

2014| Wilcox, C. E.

This case study (n=1) examines an individual who successfully used psilocybin to reduce the core symptoms of OCD for several years, and highlights avenues for future research investigating the role of serotonergic factors underlying OCD symptoms.

Long-term Amelioration of OCD Symptoms in a Patient with Chronic Consumption of Psilocybin-containing Mushrooms

2020| Cortes-Lopez, J. L., Lugo-Radillo, A.

This case report (n=1) describes the self-medication outcomes of a patient with treatment-resistant obsessive-compulsive disorder (OCD) who ingested psilocybin-containing mushrooms (2g dried weight; Psilocybe caerulescens) every 2 weeks over a 6 month period. He reported feelings of dissociation without hallucination and the disappearance of OCD symptoms 1 hour after ingestion and was able to perform most of his daily tasks and work without interruptions which meaningfully improved his wellbeing and quality of life for two weeks after each ingestion. The Yale-Brown Obsessive Compulsive Scale confirmed that his obsessive thoughts and compulsions, as well as the rumination, worry and anxiety, and checking behavior, had been significantly reduced over the course of treatment

Intranasal Ketamine and Cognitive-Behavioral Therapy for Treatment-Refractory Obsessive-Compulsive Disorder

2017| Adams, T., Bloch, M. H., Pittenger, C.

This case study (2017) presents a patient suffering from OCD that was promisingly treated with intranasal ketamine and concomitant CBT.

The Heffter Research Institute: Past and Hopeful Future

2014| Nichols, D. E.

This essay describes the history and the development of the Heffter Research Institute, in their ongoing efforts to supply psilocybin for the purposes of fundamental and applied clinical research, with a prospective outlook that psilocybin will one day be recognized to have legitimate medical value and integrated within a specialized therapeutic practice.

Safety, Tolerability, and Efficacy of Psilocybin in 9 Patients With Obsessive-Compulsive Disorder

2006| Delgado, P. L., Moreno, F. A., Taitano, E. K., Wiegand, C. B.

A preliminary study (n=9) of psilocybin (up to 21mg/70kg) found no adverse effects and improvements on OCD symptoms.

Compared

This section compares the research with psychedelics to other therapies, medicines, or treatments.

Measured

This section highlights the various measures used and their use in research.

Researchers

Who are the top researches in this area, the ones who have done the groundbreaking research.

Gaps

What do we not know at this time? Where are the gaps in our knowledge and are we closing it?

Companies

The companies that are actively engaged in researching this topic or (planning to) provide therapy focussed on this topic.

Outside Academia

This section highlights everything done outside of academia, from popular press to books and non academic research.